RS20050594A - 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis - Google Patents

3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Info

Publication number
RS20050594A
RS20050594A YUP-2005/0594A YUP20050594A RS20050594A RS 20050594 A RS20050594 A RS 20050594A YU P20050594 A YUP20050594 A YU P20050594A RS 20050594 A RS20050594 A RS 20050594A
Authority
RS
Serbia
Prior art keywords
acid derivatives
cyclohexanecarbonyl
ylmethoxy
oxazol
atherosclerosis
Prior art date
Application number
YUP-2005/0594A
Other languages
English (en)
Serbian (sr)
Inventor
Christian Stapper
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Heiner GLOMBIK
Wolfgang Wendler
Original Assignee
Sanofi-Aventis Deutschalnd Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschalnd Gmbh., filed Critical Sanofi-Aventis Deutschalnd Gmbh.,
Publication of RS20050594A publication Critical patent/RS20050594A/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
YUP-2005/0594A 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis RS20050594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
RS20050594A true RS20050594A (en) 2007-12-31

Family

ID=32920629

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0594A RS20050594A (en) 2003-02-27 2004-02-19 3-methyl-2-(3-(2-phenyl-oxazol-4- ylmethoxy)- cyclohexanecarbonyl- amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Country Status (34)

Country Link
US (5) US7335671B2 (US07365084-20080429-C00036.png)
EP (3) EP1599452B1 (US07365084-20080429-C00036.png)
JP (3) JP2006519193A (US07365084-20080429-C00036.png)
KR (3) KR20050105492A (US07365084-20080429-C00036.png)
CN (3) CN100439345C (US07365084-20080429-C00036.png)
AR (3) AR043433A1 (US07365084-20080429-C00036.png)
AT (3) ATE430738T1 (US07365084-20080429-C00036.png)
AU (3) AU2004215673B2 (US07365084-20080429-C00036.png)
BR (3) BRPI0407814A (US07365084-20080429-C00036.png)
CA (3) CA2517386A1 (US07365084-20080429-C00036.png)
CL (2) CL2004000391A1 (US07365084-20080429-C00036.png)
CO (2) CO5690578A2 (US07365084-20080429-C00036.png)
DE (4) DE10308355A1 (US07365084-20080429-C00036.png)
DK (3) DK1599452T3 (US07365084-20080429-C00036.png)
EC (2) ECSP055986A (US07365084-20080429-C00036.png)
ES (3) ES2326418T3 (US07365084-20080429-C00036.png)
HR (3) HRP20050743A2 (US07365084-20080429-C00036.png)
IL (2) IL170316A (US07365084-20080429-C00036.png)
MA (3) MA27737A1 (US07365084-20080429-C00036.png)
MX (3) MXPA05008988A (US07365084-20080429-C00036.png)
NO (3) NO20054408L (US07365084-20080429-C00036.png)
OA (2) OA13034A (US07365084-20080429-C00036.png)
PA (1) PA8596801A1 (US07365084-20080429-C00036.png)
PE (3) PE20050293A1 (US07365084-20080429-C00036.png)
PL (3) PL378437A1 (US07365084-20080429-C00036.png)
PT (3) PT1599452E (US07365084-20080429-C00036.png)
RS (1) RS20050594A (US07365084-20080429-C00036.png)
RU (3) RU2005130002A (US07365084-20080429-C00036.png)
SA (1) SA04250153A (US07365084-20080429-C00036.png)
TN (2) TNSN05204A1 (US07365084-20080429-C00036.png)
TW (3) TW200508210A (US07365084-20080429-C00036.png)
UY (2) UY28210A1 (US07365084-20080429-C00036.png)
WO (3) WO2004076426A1 (US07365084-20080429-C00036.png)
ZA (2) ZA200505765B (US07365084-20080429-C00036.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
WO2008018138A1 (fr) 2006-08-10 2008-02-14 Wood One Co., Ltd. Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
EP2246343B1 (en) 2008-02-29 2016-05-18 Nissan Chemical Industries, Ltd. Process for production of thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116184779A (zh) 2017-12-13 2023-05-30 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (en) 1997-07-16 2000-05-17 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
BR0010126A (pt) * 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
ES2203498T3 (es) 1999-07-29 2004-04-16 Eli Lilly And Company Benzofurilpiperazinas: agonistas de receptor 5-ht2c de la serotonina.
RU2002107998A (ru) * 1999-09-01 2003-11-10 АВЕНТИС ФАРМА ДОЙЧЛАНД ГмбХ (DE) Сульфонилкарбоксамидные производные, способ их получения и их применение в качестве лекарственных средств
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
DK2055302T3 (da) 2000-03-31 2014-10-27 Royalty Pharma Collection Trust Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf
EE200200601A (et) 2000-04-25 2004-04-15 Kyorin Pharmaceutical Co., Ltd. Uus stabiilne tiasolidiindiooniderivaadi kristallja meetod selle valmistamiseks
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
CZ20024003A3 (cs) 2000-06-09 2003-03-12 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, způsoby jejich výroby a použití jako léčiva
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
EP1726586A1 (en) * 2000-12-25 2006-11-29 Ono Pharmaceutical Co., Ltd. Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
BR0207285A (pt) * 2001-02-15 2004-02-10 Pfizer Producs Inc Agonistas de ppar
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
JP2005502600A (ja) * 2001-06-07 2005-01-27 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体(ppar)のモジュレーター
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
ES2278077T3 (es) 2001-08-31 2007-08-01 Sanofi-Aventis Deutschland Gmbh Derivados de diarilcicloalquilo, procedimiento para su preparacion y su uso como activadores de ppar.
EP1474385B1 (en) 2002-02-05 2009-06-10 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
EP1599453A1 (de) 2005-11-30
DE502004009690D1 (de) 2009-08-13
US20050101637A1 (en) 2005-05-12
AR043427A1 (es) 2005-07-27
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
SA04250153A (ar) 2005-12-03
PT1599453E (pt) 2009-07-14
EP1599453B1 (de) 2009-05-06
TNSN05206A1 (en) 2007-06-11
ES2287700T3 (es) 2007-12-16
CN100439347C (zh) 2008-12-03
WO2004076428A1 (de) 2004-09-10
US20080167354A1 (en) 2008-07-10
CO5690578A2 (es) 2006-10-31
UY28209A1 (es) 2004-09-30
BRPI0407907A (pt) 2006-02-14
PL378130A1 (pl) 2006-03-06
KR20050106461A (ko) 2005-11-09
AR043432A1 (es) 2005-07-27
WO2004076427A1 (de) 2004-09-10
CL2004000392A1 (es) 2005-04-22
DE502004009453D1 (de) 2009-06-18
UY28210A1 (es) 2004-09-30
EP1599452B1 (de) 2007-06-20
EP1599455A1 (de) 2005-11-30
JP2006519194A (ja) 2006-08-24
PE20040959A1 (es) 2005-01-17
AU2004215672B2 (en) 2010-01-07
US20050215596A1 (en) 2005-09-29
ECSP055985A (es) 2006-01-16
ATE435217T1 (de) 2009-07-15
MA27736A1 (fr) 2006-02-01
OA13034A (en) 2006-11-10
RU2005129995A (ru) 2006-01-27
CA2517381A1 (en) 2004-09-10
DE10308355A1 (de) 2004-12-23
ATE365159T1 (de) 2007-07-15
TW200510352A (en) 2005-03-16
ZA200505765B (en) 2006-05-31
MXPA05008951A (es) 2005-11-04
ECSP055986A (es) 2006-01-16
NO20054396L (no) 2005-11-11
CA2517386A1 (en) 2004-09-10
PL378437A1 (pl) 2006-04-03
AU2004215677B2 (en) 2010-01-07
KR20050105492A (ko) 2005-11-04
PT1599455E (pt) 2009-09-29
DE502004004139D1 (de) 2007-08-02
DK1599453T3 (da) 2009-08-24
DK1599452T3 (da) 2007-10-01
HRP20050742A2 (en) 2006-09-30
AU2004215672A1 (en) 2004-09-10
DK1599455T3 (da) 2009-11-09
AU2004215673A1 (en) 2004-09-10
NO20054396D0 (no) 2005-09-22
CN100398526C (zh) 2008-07-02
US7872034B2 (en) 2011-01-18
HRP20050744A2 (en) 2006-09-30
JP2006519199A (ja) 2006-08-24
IL170314A (en) 2010-11-30
PE20050292A1 (es) 2005-05-24
CN100439345C (zh) 2008-12-03
CO5690580A2 (es) 2006-10-31
CN1756748A (zh) 2006-04-05
US7365084B2 (en) 2008-04-29
EP1599452A1 (de) 2005-11-30
NO20054408D0 (no) 2005-09-22
MXPA05008988A (es) 2005-10-18
RU2005130002A (ru) 2006-01-27
US20080015238A1 (en) 2008-01-17
EP1599455B1 (de) 2009-07-01
CL2004000391A1 (es) 2005-01-07
RU2005129992A (ru) 2006-02-10
BRPI0407758A (pt) 2006-02-14
NO20054398D0 (no) 2005-09-22
CA2516620A1 (en) 2004-09-10
US7335671B2 (en) 2008-02-26
JP2006519193A (ja) 2006-08-24
MA27737A1 (fr) 2006-02-01
AR043433A1 (es) 2005-07-27
WO2004076426A1 (de) 2004-09-10
ZA200505768B (en) 2005-11-23
TW200508210A (en) 2005-03-01
NO20054398L (no) 2005-11-02
US20040209920A1 (en) 2004-10-21
ATE430738T1 (de) 2009-05-15
BRPI0407814A (pt) 2006-02-14
TNSN05204A1 (en) 2007-06-11
AU2004215677A1 (en) 2004-09-10
US7259177B2 (en) 2007-08-21
PL377735A1 (pl) 2006-02-20
MXPA05008995A (es) 2005-10-18
TW200500349A (en) 2005-01-01
ES2329366T3 (es) 2009-11-25
CN1753881A (zh) 2006-03-29
AU2004215673B2 (en) 2009-10-01
OA13035A (en) 2006-11-10
KR20050106462A (ko) 2005-11-09
CN1753879A (zh) 2006-03-29
PT1599452E (pt) 2007-09-12
PE20050293A1 (es) 2005-05-24
ES2326418T3 (es) 2009-10-09
MA27742A1 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
TNSN05206A1 (en) 3-methyl-2-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
RS20050019A (en) Heterocyclically substituted benzoylureas,method for their production and their use as medicaments
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
RS16704A (en) Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
HRP20050696B1 (en) 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
PL378295A1 (pl) Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
TNSN06005A1 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TNSN06004A1 (en) Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MXPA05008993A (es) Derivados de diarilcicloalquilo, metodo para su produccion y su uso como medicamentos.
HRP20050779A2 (en) Supstituted benzoylureidopyridyl-piperidine and pyrrolidine carboxylic acid derivatives, method for the production thereof and the use thereof
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
HRP20050667A2 (en) Corbonyl-amino substituted acyl phenyl urea derivatives, method for the production and use thereof
WO2008023004A8 (de) Enantiomerenreine betaagonisten, verfahren zu deren herstellungen und deren verwendung als arzneimittel
MXPA05008990A (es) Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos.
MXPA05009054A (es) Derivados de arilcicloalquilo con cadenas laterales ramificadas en calidad de moduladores de receptores ppar, metodo para su produccion y su uso como medicamentos.
TNSN05205A1 (en) Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament
WO2004033416A3 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
RS20060049A (en) Novel n-substituted indolyl-3-glycoxylic acid amides, use thereof as a medicament and method for the production thereof